Delphine Trochet
Paris, 75013, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Allele-specific RNAi therapy corrects an extracellular matrix defect in Schuurs-Hoeijmakers syndrome.
Journal: American journal of human genetics
Published: April 22, 2025
Development of versatile allele-specific siRNAs able to silence all the dominant dynamin 2 mutations.
Journal: Molecular therapy. Nucleic acids
Published: March 28, 2022
Benefits of therapy by dynamin-2-mutant-specific silencing are maintained with time in a mouse model of dominant centronuclear myopathy.
Journal: Molecular therapy. Nucleic acids
Published: August 11, 2021
A review of Dynamin 2 involvement in cancers highlights a promising therapeutic target.
Journal: Journal of experimental & clinical cancer research : CR
Published: May 26, 2021
Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy.
Journal: EMBO molecular medicine
Published: December 17, 2017
Reprogramming the Dynamin 2 mRNA by Spliceosome-mediated RNA Trans-splicing.
Journal: Molecular therapy. Nucleic acids
Published: April 21, 2016
Telomere regulation during ageing and tumorigenesis of the grey mouse lemur.
Journal: Biochimie
Published: January 14, 2015
Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls.
Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls.
Journal: Current gene therapy
Published: November 06, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026